New members join the Rare Disease Action Forum

31 Jan, 2017

In January 2017, Alexion Pharmaceuticals, Amicus Therapeutics and Sanofi Genzyme joined the Rare Disease Action Forum (RDAF). With this growth, the Forum now includes eight member companies that are all important contributors in the field of rare diseases. Using a multi-stakeholder approach, the RDAF aims at developing and implementing solutions to improve access to diagnosis and treatment for patients with rare diseases in Switzerland. Press release (PDF): English, German, French, Italian

Joint statement on the KVV/OAMal and KLV/OPAS revision

The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement highlights the potential negative impacts of the revision, including the following: -...

The Rare Disease Action Forum (RDAF) advocates for a fair and rapid access to high-quality treatment for patients with rare diseases in Switzerland.

In line with this concern, the RDAF would like to draw attention to the fact that the planned revision of the Health Insurance Ordinance (KVV), contrary to its stated objective, threatens patients’ access to treatment. Read our media release here.